Esophagus cancer
Conditions
Interventions
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with pathologically or clinically confirmed recurrent or distant metastatic esophageal squamous cell carcinoma (AJCC 8th edition); 2. Age >= 18 years; 3. Patients who are treatment-naive in the first-line setting or are receiving first-line systemic immunotherapy including Tislelizumab, with at least 2 cycles of first-line therapy before progression, and continuing Tislelizumab treatment after progression in the second-line setting; 4. For second-line patients, during first-line treatment, they must have received at least 2 cycles of PD-1/PD-L1 therapy, including but not limited to Tislelizumab; 5. Good compliance and willingness to undergo long-term follow-up.
Exclusion criteria
Exclusion criteria: 1. Simultaneously participating in another blinded clinical study; 2. Presence of other active malignant tumors or multiple primary cancers; 3. Pregnant or breastfeeding women, or male and female patients planning to conceive during the study; 4. Other situations deemed by the investigator as unsuitable for study inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in therapeutic effect;Safety; | — |
Countries
China
Contacts
Public ContactGui Yan
Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed